Cargando…
Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
Unlike traditional chemotherapy agents which are generally cytotoxic to all cells, targeted anti-cancer therapies are designed to specifically target proliferation mechanisms in cancer cells but spare normal cells, resulting in high potency and reduced toxicity. There has therefore been a rapid incr...
Autores principales: | Rosario, Roseanne, Cui, Wanyuan, Anderson, Richard A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346327/ https://www.ncbi.nlm.nih.gov/pubmed/35928672 http://dx.doi.org/10.1530/RAF-22-0020 |
Ejemplares similares
-
The molecular mechanisms that underlie fragile X-associated premature ovarian insufficiency: is it RNA or protein based?
por: Rosario, Roseanne, et al.
Publicado: (2020) -
Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials
por: Cui, Wanyuan, et al.
Publicado: (2022) -
Evidence for a fragile X messenger ribonucleoprotein 1 (FMR1) mRNA gain‐of‐function toxicity mechanism contributing to the pathogenesis of fragile X‐associated premature ovarian insufficiency
por: Rosario, Roseanne, et al.
Publicado: (2022) -
Potential Targeted Therapies in Ovarian Cancer
por: Sisman, Yagmur, et al.
Publicado: (2022) -
RNA immunoprecipitation identifies novel targets of DAZL in human foetal ovary
por: Rosario, Roseanne, et al.
Publicado: (2017)